Janssen to file daratumumab in 2015 on PhII data
This article was originally published in Scrip
Executive Summary
Janssen (Johnson & Johnson) plans to submit a biologic licensing application to the US FDA and a marketing authorization application to the EMA this year for daratumumab in double refractory multiple myeloma. The submission will be based on Phase II data, which will be presented at the upcoming American Society of Clinical Oncology (ASCO) meeting.